http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2704998-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e0289b5c7b14585b669edc2580623cb4 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-87 |
| filingDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4322054e6e5ec0f223f01e0ffda7cb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e44b40d4ab49f854638ac2d173c9961 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bee503fd54e9d9cfcf7ccb2183740cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53e94a4306195a7e35e95cc9904df16d |
| publicationDate | 2019-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2704998-C1 |
| titleOfInvention | Method of reversible inhibition in tumor cells of hepatocellular carcinoma of gene expression coding synthesis of apolipoprotein b |
| abstract | FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and specifically to reversible inhibition of hepatocellular carcinoma in tumor cells of gene expression coding synthesis of apolipoprotein B. Method involves introducing into a medium containing Huh7 tumor cells human hepatocellular carcinoma, a dispersion of lipid nanoparticles of modified magnetite crystals obtained by mixing 138 pts. wt. magnetite crystals with size of 23–27 nm with 1 pts. wt. mixture of cholesterol lipids, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)dododecan-2-ol and 1,2-dimyristoyl-sn-glycero-methoxy(polyethyleneglycol)-2000, taken in weight ratio of 15:7:75:3, respectively, at first with 60,000 pts. wt. chloroform, followed by 82,240 pts. wt. N-methyl-2-pyrrolidone, treatment of the mixture with ultrasound for 0.5–7.0 hours with ultrasound power of 116–580 W, removal of chloroform, addition of water in dispersion of 400–600 % of the volume of the dispersion, dialysis of the obtained dispersion against water for 24–48 hours in a dialysis bag with pore size of 25–50 kilodaltons, concentration of dispersion to content of magnetite 0.7–2.8 mg/ml under vacuum, mixing 1 pts. wt. obtained dispersion of modified magnetite crystals with a solution of low interfering ribonucleic acid in an aqueous solution of sodium acetate containing 0.05–0.20 pts. wt. low interfering ribonucleic acid, purification of the obtained dispersion by re-dialysis against water, addition of a sodium phosphate buffer into the purified dispersion to obtain a dispersion with ionic force of 0.15 M. Then one performs treatment for 1–3 h with an alternating magnetic field with inductance of 50–100 millitesla.EFFECT: invention increases degree of reversible inhibition of gene expression coding synthesis of apolipoprotein B in tumor cells of Huh7 human hepatocellular carcinoma.1 cl, 4 ex |
| priorityDate | 2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.